Sepsis Pipeline Gains Momentum: 28+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's "Sepsis Pipeline Insight 2026" report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in the Sepsis pipeline landscape. It covers the Sepsis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sepsis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Sepsis Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Sepsis Pipeline Report
• On August 05, 2026- CorMedix Therapeutics initiated a study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.
• DelveInsight's Sepsis Pipeline report depicts a robust space with 28+ active players working to develop 30+ pipeline therapies for Sepsis treatment.
• The leading Sepsis Companies such as Vivacelle Bio, Inotrem, AUROBAC Therapeutics, Aptahem AB, Shanghai Yidian Pharmaceutical Technology Development, Swedish Orphan Biovitrum AB, SNIPR Biome, Matisse Pharmaceuticals, Grand Pharma, ABIONYX Pharma, AdrenoMed AG, Bayer, Artcline GmbH, AstraZeneca, and Op-T LLC and others.
• Promising Sepsis Therapies such as Cefiderocol, Daptomycin, E5564, Meropenem, STC314 Injection, Thymosin alpha 1, Ubiquinol, Drotrecogin alfa, Resatorvid, sPLA2 Inhibitor and others.

Want to know which companies are leading innovation in Sepsis? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Sepsis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Sepsis Pipeline Report also highlights the unmet needs with respect to the Sepsis.

Sepsis Overview
Sepsis is a serious and progressive medical condition triggered by the body's dysregulated response to infection, leading to widespread inflammation and potentially life-threatening organ dysfunction. It occurs more frequently in elderly individuals, patients with cancer, and those with weakened immune systems, contributing significantly to global mortality, morbidity, healthcare burden, and costs. Disease progression to severe sepsis or septic shock is associated with hypotension, multi-organ failure, and increased risk of death, driven by disturbances in inflammatory, immune, coagulation, and oxygen-utilization pathways. In advanced stages, sepsis can result in chronic critical illness marked by profound immune suppression and metabolic dysfunction. Common symptoms include fever or hypothermia, rapid heart rate and breathing, confusion, chills, sweating, pain, skin rash, nausea, reduced urination, dizziness, while infants may present with irritability and lethargy.

Sepsis Emerging Drugs Profile
• VBI-S: Vivacelle Bio
VBI-S is an investigational lipid-based therapy composed of micelles and liposomes, designed to restore blood pressure in septic shock patients with absolute or relative hypovolemia. The therapy is being evaluated in the Phase III VBI-S-02 trial for its ability to elevate mean arterial pressure and reduce vasopressor requirements in patients unresponsive to standard fluid resuscitation. The study also assesses improvements in organ function, oxygenation, and post-treatment survival outcomes.

• Nangibotide: Inotrem
Nangibotide is a TREM-1 inhibitory peptide designed to improve survival in septic shock by restoring vascular integrity and regulating the inflammatory response. Its active component, LR12, is a synthetically produced 12-amino-acid peptide that functions as a decoy receptor, blocking the interaction between TREM-1 and its ligand. In preclinical septic shock models, Nangibotide demonstrated improved survival outcomes and normalization of inflammatory and vascular dysfunction, and it later received EMA PRIME designation in 2017 and FDA Fast Track designation in 2019 for septic shock treatment. The drug is currently in Phase II stage of its development.

• ATX101: AUROBAC Therapeutics
ATX101 is a first-in-class host-targeted investigational therapy being developed by for the treatment of early septic shock. The therapy is designed to target the loss of vascular integrity, a key pathophysiological driver of septic shock, with the goal of preventing disease progression and improving patient outcomes. ATX101 is currently in Phase I clinical development and represents a novel precision medicine approach for sepsis management.

• Apta-1:Aptahem AB
Apta-1 is a first-in-class RNA aptamer therapeutic being developed by Aptahem AB for the treatment of sepsis and septic shock. The therapy is designed to exert immunomodulatory, anti-inflammatory, and anticoagulant effects simultaneously, aiming to restore immune balance and reduce organ damage during severe infection. Apta-1 has demonstrated favorable safety and tolerability in Phase I studies and is being advanced as a novel multi-target approach for sepsis management.

If you're tracking ongoing Sepsis Clinical trials, this press release is a must-read @ https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Sepsis Companies
Vivacelle Bio, Inotrem, AUROBAC Therapeutics, Aptahem AB, Shanghai Yidian Pharmaceutical Technology Development, Swedish Orphan Biovitrum AB, SNIPR Biome, Matisse Pharmaceuticals, Grand Pharma, ABIONYX Pharma, AdrenoMed AG, Bayer, Artcline GmbH, AstraZeneca, and Op-T LLC and others.

The Sepsis Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sepsis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.
• Sepsis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sepsis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sepsis market.

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Sepsis Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sepsis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Sepsis Pipeline Report covers it all @ https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Sepsis Pipeline Report
• Coverage- Global
• Sepsis Companies- Vivacelle Bio, Inotrem, AUROBAC Therapeutics, Aptahem AB, Shanghai Yidian Pharmaceutical Technology Development, Swedish Orphan Biovitrum AB, SNIPR Biome, Matisse Pharmaceuticals, Grand Pharma, ABIONYX Pharma, AdrenoMed AG, Bayer, Artcline GmbH, AstraZeneca, and Op-T LLC and others.
• Sepsis Therapies- Cefiderocol, Daptomycin, E5564, Meropenem, STC314 Injection, Thymosin alpha 1, Ubiquinol, Drotrecogin alfa, Resatorvid, sPLA2 Inhibitor and others.
• Sepsis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sepsis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Sepsis Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Sepsis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sepsis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Drug profiles in the detailed report.....
12. Early Stage Products (Phase I/II)
13. Drug Name: Company Name
14. Drug profiles in the detailed report.....
15. Preclinical and Discovery Stage Products
16. Drug profiles in the zetailed report.....
17. Inactive Products
18. Sepsis Key Companies
19. Sepsis Key Products
20. Sepsis- Unmet Needs
21. Sepsis- Market Drivers and Barriers
22. Sepsis- Future Perspectives and Conclusion
23. Sepsis Analyst Views
24. Sepsis Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.